Can patients stop Anti-Rejection drugs sooner after transplant?
NCT ID NCT07302776
First seen Jan 04, 2026 · Last updated Jun 20, 2026 · Updated 24 times
Summary
This study tests whether patients who receive a stem cell transplant can safely stop the immunosuppressant tacrolimus earlier than usual. Fifty participants with blood cancers or disorders will begin tapering tacrolimus around day 60 after transplant, aiming to stop by day 88. The goal is to see if this reduces side effects without increasing graft-versus-host disease.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MYELODYSPLASTIC SYNDROMES are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Stanford University
Palo Alto, California, 94304, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Tacrolimus
What this could lead to
If successful, this could show that stopping immunosuppression earlier is safe after modern transplant methods, potentially reducing side effects for patients.
What could go wrong
This is a small, early-phase trial, so results may not apply broadly. There is a risk of severe graft-versus-host disease if tacrolimus is stopped too soon.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.